Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Arthur F. Ryan Sells 100 Shares of Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the sale, the director now directly owns 17,882 shares in the company, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $1,044.66 on Wednesday. The stock’s 50-day simple moving average is $987.40 and its two-hundred day simple moving average is $952.81. Regeneron Pharmaceuticals, Inc. has a twelve month low of $688.52 and a twelve month high of $1,081.17. The firm has a market capitalization of $115.11 billion, a P/E ratio of 30.86, a P/E/G ratio of 2.17 and a beta of 0.13. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The business had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. UBS Group lifted their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Argus upped their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $1,229.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, June 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,027.55.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Marcum Wealth LLC purchased a new position in Regeneron Pharmaceuticals in the second quarter worth $203,000. Massmutual Trust Co. FSB ADV lifted its stake in Regeneron Pharmaceuticals by 15.1% during the second quarter. Massmutual Trust Co. FSB ADV now owns 4,680 shares of the biopharmaceutical company’s stock worth $4,919,000 after purchasing an additional 615 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 22.5% in the 2nd quarter. GAMMA Investing LLC now owns 1,083 shares of the biopharmaceutical company’s stock worth $1,138,000 after purchasing an additional 199 shares in the last quarter. Keynote Financial Services LLC bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $481,000. Finally, Hamilton Wealth LLC raised its holdings in shares of Regeneron Pharmaceuticals by 72.0% during the 1st quarter. Hamilton Wealth LLC now owns 461 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 193 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.